Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.
Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, Kazami Y, Washizaki A, Masuta Y, Suzuki R, Matsuda K, Komori M, Morey AL, Ishimoto K, Nakata M, Hasunuma T, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Sato N. Akahata W, et al. Cell Rep Med. 2023 Aug 15;4(8):101134. doi: 10.1016/j.xcrm.2023.101134. Cell Rep Med. 2023. PMID: 37586325 Free PMC article. Clinical Trial.
saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.
Komori M, Nogimori T, Morey AL, Sekida T, Ishimoto K, Hassett MR, Masuta Y, Ode H, Tamura T, Suzuki R, Alexander J, Kido Y, Matsuda K, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Akahata W. Komori M, et al. Among authors: akahata w. Nat Commun. 2023 May 19;14(1):2810. doi: 10.1038/s41467-023-38457-x. Nat Commun. 2023. PMID: 37208330 Free PMC article.
Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine.
Aboshi M, Matsuda K, Kawakami D, Kono K, Kazami Y, Sekida T, Komori M, Morey AL, Suga S, Smith JF, Fukuhara T, Iwatani Y, Yamamoto T, Sato N, Akahata W. Aboshi M, et al. Among authors: akahata w. iScience. 2024 Jan 22;27(2):108964. doi: 10.1016/j.isci.2024.108964. eCollection 2024 Feb 16. iScience. 2024. PMID: 38352232 Free PMC article.
A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
Thoresen D, Matsuda K, Urakami A, Ngwe Tun MM, Nomura T, Moi ML, Watanabe Y, Ishikawa M, Hau TTT, Yamamoto H, Suzaki Y, Ami Y, Smith JF, Matano T, Morita K, Akahata W. Thoresen D, et al. Among authors: akahata w. J Virol. 2024 May 14;98(5):e0023924. doi: 10.1128/jvi.00239-24. Epub 2024 Apr 22. J Virol. 2024. PMID: 38647327 Free PMC article.
Reassessing therapeutic antibodies for neglected and tropical diseases.
Hooft van Huijsduijnen R, Kojima S, Carter D, Okabe H, Sato A, Akahata W, Wells TNC, Katsuno K. Hooft van Huijsduijnen R, et al. Among authors: akahata w. PLoS Negl Trop Dis. 2020 Jan 30;14(1):e0007860. doi: 10.1371/journal.pntd.0007860. eCollection 2020 Jan. PLoS Negl Trop Dis. 2020. PMID: 31999695 Free PMC article. Review.
A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates.
Ko SY, Akahata W, Yang ES, Kong WP, Burke CW, Honnold SP, Nichols DK, Huang YS, Schieber GL, Carlton K, DaSilva L, Traina-Dorge V, Vanlandingham DL, Tsybovsky Y, Stephens T, Baxa U, Higgs S, Roy CJ, Glass PJ, Mascola JR, Nabel GJ, Rao SS. Ko SY, et al. Among authors: akahata w. Sci Transl Med. 2019 May 15;11(492):eaav3113. doi: 10.1126/scitranslmed.aav3113. Sci Transl Med. 2019. PMID: 31092692
Structural studies of Chikungunya virus maturation.
Yap ML, Klose T, Urakami A, Hasan SS, Akahata W, Rossmann MG. Yap ML, et al. Among authors: akahata w. Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13703-13707. doi: 10.1073/pnas.1713166114. Epub 2017 Dec 4. Proc Natl Acad Sci U S A. 2017. PMID: 29203665 Free PMC article.
27 results